KDR and breast cancer: Our data suggests that blockade of VEGFR1 and VEGFR2 (e.g., bevacizumab and GU81) can induce an increase in MDSC infiltration, while selective blockade of VEGFR2 limits MDSC accumulation in this xenograft model of breast cancer.